mTORC1 promotes survival through translational control of Mcl-1
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a frequent occurrence in human cancers and a major promoter of chemotherapeutic resistance. Inhibition of one downstream target in this pathway, mTORC1, has shown potential to improve chemosensitivity. However, the mechanisms and genetic modifications that confer sensitivity to mTORC1 inhibitors remain unclear. Here, we demonstrate that loss of TSC2 in the E μ- myc murine lymphoma model leads to mTORC1 activation and accelerated oncogenesis caused by a defective apoptotic program despite compromised AKT phosphorylation. Tumors from Tsc2 +/− E μ- Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin. We identified myeloid cell leukemia sequence 1 ( Mcl-1 ), a bcl-2 like family member, as a translationally regulated genetic determinant of mTORC1-dependent survival. Our results indicate that the extent by which rapamycin can modulate expression of Mcl-1 is an important feature of the rapamycin response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TORC1 inhibition, via loss of 4EBP1 (also referred to as EIF4EBP1) phosphorylation, results in a decrease of MCL-1 protein expression in these cancers (37–40).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous studies had demonstrated that efficient translation of MCL-1 mRNA requires cap-dependent translation in some cancers (36–38).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Self-citation
Cited by
Items 201–285 of 285
PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma
Oyama, T., Brashears, C. B., Rathore, R., Benedict-Hamilton, H. M., Caldwell, K. E., Dirckx, N., Hawkins, W. G., & Tine, B. A. V. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07378-6 · Cited by 16
“However, in FOXO3 KO cells, the transcriptional induction of PUMA by either of the combined treatments was limited, and the mRNA expression level of PUMA in FOXO3 KO cells was similar to that in FOXO1/3 double KO cells (Fig.”
Leclerc, G. J., DeSalvo, J., Du, J., Gao, N., Leclerc, G. M., Lehrman, M. A., Lampidis, T. J., & Barredo, J. C. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.08.007 · Cited by 14
Kazyken, D., Lentz, S. I., Wadley, M., & Fingar, D. C. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105097 · Cited by 13
Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma
Lin, Y. H., Wang, H., Fiore, A., Förster, M., Tung, L. T., Belle, J. I., Robert, F., Pelletier, J., Langlais, D., & Nijnik, A. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16554 · Cited by 12
Self-citationYu, J., Jin, Y., Chen, X., Fang, C., Zhang, Z., Chen, L., & Xu, G. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00676-4 · Cited by 11
“Studies show that the PI3K/AKT pathway inhibition significantly diminishes MCL-1 protein levels through dephosphorylation/activation of GSK3a/b, triggering MCL-1 degradation [49] as well as through translation inhibition [50].”
BackgroundFine tuning of the transcription juggernaut: A sweet and sour saga of acetylation and ubiquitination
Ghosh, A., Chakraborty, P., & Biswas, D. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194944 · Cited by 12
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
Galimberti, S., & Petrini, M. (2010) · Cancer Management and Research · doi:10.2147/cmar.s7960 · Cited by 14
“Like c-Myc, Mcl-1 is overexpressed in MCL;(67) this gene, a member of the bcl-2 family, is translationally regulated by mTORC1 and is involved in the antiapoptotic action of mTOR.(68) Syk, a tyrosine kinase involved in B-cell receptor signalling, has been reported to be amplified at the DNA level and overexpressed at…”
Jeong, M., Jeong, M. H., Kim, J. E., Cho, S., Lee, K. J., Park, S. I., Sohn, J., & Park, Y. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-00247-0 · Cited by 12
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“To investigate the basis for increased MCL-1 dependent priming in LKB1-de fi cient cells, we examined MCL-1 protein expression levels, as this is highly dependent on cap-dependent translational regulated by mTOR 52 (which is regulated by AMPK).”
Wei, M., Cao, Z., Dong, L., Wang, W., Wei, M., Ji, L., Duan, L., Sun, H., & Zheng, M. (2025) · Oncology Letters · doi:10.3892/ol.2025.15272 · Cited by 19
“Activated mTORC1 then hierarchically phosphorylates 4E‑BP1, liberating eIF4E to drive cap‑dependent translation that preferentially maintains short‑lived anti‑apoptotic proteins such as MCL‑1, thereby counteracting sorafenib‑induced apoptosis (76).”
Lee, I., Doepner, M., Weissenrieder, J., Majer, A. D., Mercado, S., Estell, A., Natale, C. A., Sung, P. J., Foskett, J. K., Carroll, M. P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0478 · Cited by 10
Bcl-2highmantle cell lymphoma cells are sensitized to acadesine with ABT-199
Montraveta, A., Xargay‐Torrent, S., Rosich, L., López‐Guerra, M., Roldán, J., Rodríguez, V., Lee‐Vergés, E., de Frías, M., Campàs, C., Campo, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4230 · Cited by 10
“Supporting this, other compounds that target mTOR pathway were also described to inhibit Mcl-1 at a translational level in lymphomas [44, 49, 50].”
BackgroundDUB-le Trouble for Cell Survival
Opferman, J. T., & Green, D. R. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.011 · Cited by 11
“In an AKT-driven, Em-Myc lymphoma mouse model, translational regulation of MCL-1 by mTOR has been implicated in promoting lymphomagenesis (Mills et al., 2008).”
BackgroundChemistry and Pharmacology of Rapamycin and Its Derivatives
Abraham, R. T., Gibbons, J. J., & Graziani, E. I. (2010) · The Enzymes · doi:10.1016/s1874-6047(10)27017-8 · Cited by 11
Tanigawa (2010) · International Journal of Oncology · doi:10.3892/ijo_00000778 · Cited by 11
Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy
Dong, S., Matossian, M. D., Yousefi, H., Khosla, M., Collins‐Burow, B. M., Burow, M. E., & Alahari, S. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-37058-4 · Cited by 9
Risberg, K., Redalen, K. R., Sønstevold, L., Bjørnetrø, T., Sølvernes, J., & Ree, A. H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2600-y · Cited by 11
“The MAPK and PI3K-AKT signaling pathways merge at the mTOR complex, which promotes cell survival through phosphorylation of S6 and the resulting increase in Mcl-1 protein translation [28].”
BackgroundZhen, M., Wang, F., Wu, S., Zhao, Y., Liu, P., & Yin, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.14326 · Cited by 9
“, showed that mTORC1 dictates Mcl-1’s translation [28].”
BackgroundNarla, S. T., Bushnell, D. S., Duara, J. L., & Bates, C. M. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.01.004 · Cited by 8
Manni, S., Pesavento, M., Spinello, Z., Saggin, L., Arjomand, A., Fregnani, A., Tubi, L. Q., Scapinello, G., Gurrieri, C., Semenzato, G., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.935023 · Cited by 11
“, 2007) or the mTORC1 (Mills et al., 2008) cascades have been implicated in the regulation of Mcl-1 translation.”
BackgroundIncreased Expression of the Antiapoptotic Protein MCL1 in Canine Mast Cell Tumors
Amagai, Y., Tanaka, A., Matsuda, A., Oida, K., Jung, K., Nishikawa, S., Jang, H., Ishizaka, S., & Matsuda, H. (2013) · Journal of Veterinary Medical Science · doi:10.1292/jvms.13-0025 · Cited by 8
“In contrast, both PD98059 and AG490, which did not suppress the proliferation of the cells, dramatically enhanced MCL1 expression in BR cells (Fig.”
BackgroundInfluentialBirkinshaw, R. W. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00717-4 · Cited by 8
Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
Rubio‐Patiño, C., Bossowski, J. P., Villa, E., Mondragón, L., Zunino, B., Proïcs, E., Chiche, J., Bost, F., Verhoeyen, E., & Ricci, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12309 · Cited by 8
“Additionally, it has been described that mTOR pathway regulates Mcl-1 by 4EBP1/mTORC1dependent translation [19, 20, 25].”
BackgroundNDRG2 Sensitizes Myeloid Leukemia to Arsenic Trioxide via GSK3β–NDRG2–PP2A Complex Formation
Park, S., Han, H.-T., Oh, S., Kim, D. H., Jeong, J.-W., Lee, K. W., Kim, M.-J., Lim, J., Cho, Y. Y., Hwangbo, C., et al. (2019) · Cells · doi:10.3390/cells8050495 · Cited by 7
“It is known that Mcl-1 contributes to protect cells from apoptosis in APL cells [19].”
BackgroundThe self-renewal dental pulp stem cell microtissues challenged by a toxic dental monomer
Kaufman, G., Kiburi, N. M., & Škrtić, D. (2020) · Bioscience Reports · doi:10.1042/bsr20200210 · Cited by 7
“…of cells under adequate nutritional and environmental conditions and its activation is dependent on two complexes named mTOR complex1 and 2 (mTORC1 and mTORC2, respectively) [19,20]. mTORC1 controls proteins synthesis and cell survival through the phosphorylation of specific substances [21,22].”
MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis
Gui, W., Páral, P., Dhamija, B., Hagag, E., Dusa, M., Humajová, J., Francová, P., Kučka, J., Pankrác, J., Schütz, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66831-4 · Cited by 9
“Reducing the high level of MCL1 in tumors has been suggested as a mechanism of action of several anti-cancer agents targeting mTOR signaling 18 – 21 .”
Bao, X., Chen, Y., Chang, J., Du, J., Yang, C., Wu, Y., Yu, S., Li, M., Chen, S., Yang, M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13658-3 · Cited by 6
“Targeting the PI3K/mTOR pathway further inhibits MCL-1 translation and expression through dephosphorylation of GSK3α/β [60] and can also increase the anti-AML activity of BCL-2 inhibitors [40].”
Self-citationMcNamara, M. C., Hosios, A. M., Torrence, M. E., Zhao, T., Fraser, C. S., Wilkinson, M. E., Kwiatkowski, D. J., Henske, E. P., Wu, C., Sarosiek, K. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105458 · Cited by 8
Dependence of p53-deficient cells on the DHX9 DExH-box helicase
Lee, T., & Pelletier, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15889 · Cited by 6
“TSC2+/−Eμ-Myc lymphomas retained wildtype p53, as determined by sequencing across all p53 coding exons and Western blot analysis following γ-irradiation [20].”
MethodSelf-citationBadr, G., Zahran, A. M., Omar, H. E.-D. M., Barsoum, M. A., & Mahmoud, M. H. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1595054 · Cited by 6
Scott, S. C., Farago, A. F., Lai, W. V., ZAHURAK, M. L., Rudek, M. A., Murray, J., Carducci, M. A., Uziel, T., Takebe, N., Gore, S. D., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04760-1 · Cited by 7
“The TORC1 complex is necessary for mRNA cap-dependent translation of multiple proteins, including MCL-1, and acts via phosphorylation of targets including initiation factor 4EBP1 and ribosomal protein S6 [16, 17].”
Potts, M. A., Mizutani, S., Deng, Y., Vaidyanathan, S., Ting, K., Giner, G., Sridhar, S., Shenoy, G., Liao, Y., Diepstraten, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62615-y · Cited by 9
“This fi nding is consistent with other reports where aberrant mTORC1 activation during Myc-driven lymphomagenesis through loss of TSC2 or constitutive AKT expression obviated the pressure to lose p53 pathway function 36,55 .”
InfluentialLegrand, N., Pradier, A., Poulain, L., Mouche, S., Birsen, R., Larrue, C., Simonetta, F., & Tamburini, J. (2021) · Cancers · doi:10.3390/cancers13235966 · Cited by 7
“Mechanistically, we observed that loss of AMPK was accompanied by an increased Mcl1 and Bcl-xL detection, which could be explained by an increased translation of these proteins dependent on mTORC1 activation in AMPK KO cells [20,21].”
BackgroundFunction of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma
Zhu, M., & Zhang, Y. (2017) · Hepatoma Research · doi:10.20517/2394-5079.2017.14 · Cited by 5
“[66] There was a report that described that activation of mTORC1 was of vital importance to be a potent antiapoptotic signal through Mcl-1 which is a translationally regulated genetic determinant of mTORC1-dependent survival.[67] And a recent study demonstrated that metformin-induced apoptosis in HCC was mediated by t…”
BackgroundExpression of Bcl-xL and Mcl-1 in the Nonmelanoma Skin Cancers of Renal Transplant Recipients
Burke, M., Morais, C., Oliver, K. A., Lambie, D., Gobe, G. C., Carroll, R. P., Staatz, C. E., Sinnya, S., Soyer, H. P., Winterford, C. M., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpqnb5wa3plqbk · Cited by 5
Di, T., Luo, Q., Song, J.-T., Yan, X.-L., Zhang, L., Pan, W., Guo, Y., Lu, F., Sun, Y.-T., Xia, Z., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112615 · Cited by 5
Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy
Dong, S., & Alahari, S. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1408107 · Cited by 5
“PI3K/AKT/mTORC1 aberrant activation is one of the most commonly deregulated pathways in TNBCs (Cancer Genome Atlas, 2012), and Mcl-1 overexpression is one reason of drug resistance to everolimus therapy in TNBCs (Mills et al., 2008).”
BackgroundmTOR and Regulation of Translation
Tsukumo, Y., Laplante, M., Parsyan, A. E., Ruggero, D., & Fonseca, B. D. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_15 · Cited by 5
The Role of mTOR, Autophagy, Apoptosis, and Oxidative Stress During Toxic Metal Injury
Chatterjee, S., Munshi, C., & Bhattacharya, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00013-x · Cited by 4
FGF7 peptide (FGF7p) mimetic mitigates bladder urothelial injury from cyclophosphamide
Narla, S. T., Rice, L. P., Ostrov, D. A., Swarts, S. G., Siemann, D. W., Bushnell, D. S., Holden, J. G., Duara, J. L., & Bates, C. M. (2022) · Physiological Reports · doi:10.14814/phy2.15241 · Cited by 4
PI3K/AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Kong, D., & Zhang, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00012-2 · Cited by 5
Gholizadeh, E., Zangene, E., Parsons, A., Kontro, M., Heckman, C. A., & Jafari, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118647 · Cited by 6
Fonseca, B. D., & Proud, C. G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_9 · Cited by 5
“1 mRNA may, in some instances, also be regulated at the translational level by mTORC1 [61].”
Apoptosis-induced FGF signalling promotes non-cell autonomous resistance to cell deathPreprint
Bock, F. J., Cloix, C., Zerbst, D., & Tait, S. W. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.12.199430 · Cited by 3
Li, F., Bondra, K. M., Wang, H., Kurmashev, D., Mukherjee, B., Kanji, S., Habib, A. A., Chen, Y., Zheng, S., Burma, S., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf068 · Cited by 3
Stewart, M. L., Gibbs, J., Watanabe‐Smith, K., Nguyen, A. H., Kenna, I., Thiel-Klare, K., Kaempf, A. J., Bottomly, D., Kurtz, S. E., Eide, C. A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102526 · Cited by 5
Hong, J., Zheng, W., & Cai, X. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220830145026 · Cited by 3
Verghese, S., Waghmare, I., Singh, S. R., & Kango‐Singh, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8232-1_9 · Cited by 3
Potts, M. A., Mizutani, S.-Y., Deng, Y., Vaidyanathan, S., Ting, K. E., Giner, G., Sridhar, S., Liao, Y., Diepstraten, S. T., Kueh, A., et al. (2022) · bioRxiv · doi:10.1101/2022.02.16.480657
Verghese, S., Waghmare, I., Singh, S. R., & Kango‐Singh, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-42246-2_8 · Cited by 1
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Ahmed, N. A., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Discover Oncology · doi:10.1007/s12672-026-05066-1 · Cited by 1
“For instance, CDK9 inhibitors (which affect transcriptional elongation of MYC) [88], or mTORC1 inhibitors (which can diminish MYC translation) [89], might combine well with RUNX1-releasing therapy.”
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Ahmed, N. A., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156607 · Cited by 1
Hepatic, Pancreatic and Biliary Cancers
Sanders, J. A., & Gruppuso, P. A. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_30 · Cited by 1
Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy
Floros, K. V., Faber, A. C., & Harada, H. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_7 · Cited by 1
Li, J., Sugimoto, E., Yamamoto, K., Dai, Y., Zhang, W., Chang, Y. A., Nakahara, J., Yabushita, T., Kitamura, T., Park, S., et al. (2025) · Cancer Science · doi:10.1111/cas.70170 · Cited by 1
PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics
Chopra, S. S., & Cantley, L. C. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_1 · Cited by 1
Small Molecule–Mediated Simultaneous Induction of Apoptosis and Autophagy
Jinka, S., & Banerjee, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805420-8.00014-7 · Cited by 2
Targeting the mTORC2 signaling complex in B cell malignanciesPreprint
Liao, W., Jordaan, G., Benavides-Serrato, A., Holmes, B., Gera, J., & Sharma, S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/564500 · Cited by 2
“The activation of PI3K/Akt/mTOR overall results in upregulation of anti-apoptotic genes such as Mcl1 and XIAP that promote survival of leukemic cells [7,12,13].”
BackgroundAmplicon structure creates collateral therapeutic vulnerability in cancerPreprint
Bei, Y., Bramé, L., Kirchner, M., Fritsche‐Guenther, R., Kunz, S., Bhattacharya, A., Köppke, J. K. C., Proba, J., Wittstruck, N., Sidorova, O. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.08.506647 · Cited by 1
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS -mutant lung cancersPreprint
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., Clark, S. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.510137 · Cited by 1
Terra, L. F. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2013.tde-06082013-113611 · Cited by 1
Targeting the mTOR Pathway for Tumor Therapeutics
Chen, W. (2009) · Wiley eBooks · doi:10.1002/9780470538951.ch22
mTOR inhibition as a therapeutic strategy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
Davies, D. M. (2011) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 1
Assessment of therapeutic targets in experimental models of Myc-induced lymphoma
Forshell, L. P. (2011)
JB Review Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis
Hoshii, T., Matsuda, S., & Hirao, A. (2014)
Mechanisms of CXL017: targeting drug resistant cancer
Hermanson, L., & Lee, D. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
The Role of MCL-1 in the Heart: Gateway from Life to Death
Wang, X. (2014) · doi:10.21007/etd.cghs.2014.0342 · Cited by 1
“In addition, Mcl-1 mRNA translation is regulated by mTORC1 pathway (Mills et al. 2008).”
BackgroundLarge-Scale Analysis of Cell Death Phenotypic HeterogeneityPreprint
Inde, Z., Forcina, G. C., Denton, K., & Dixon, S. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.28.970079
“Moreover, we observed that inhibition of JNK function using the small molecule inhibitor JNKi VIII (Miura et al., 2018) inhibited JUN expression and phosphorylation, and specifically blocked MCL1 accumulation in response to MEKi treatment, without affecting BCL-xL or BIM levels (Figure 5E).”
BackgroundResultInfluentialCzabotar, P. E. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738696726.793583619
Tavernarakis, N., & Nikoletopoulou, V. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13381960.14750137
Wong, K. K. V., Gazali, A. M., Zamri, N. B., Rullah, K., & Aluwi, M. F. F. M. (2022) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416522300024
Data from Silibinin inhibits translation initiation: implications for anticancer therapy
Lin, C., Sukarieh, R., & Pelletier, J. (2023) · doi:10.1158/1535-7163.c.6531872
Self-citationData from Silibinin inhibits translation initiation: implications for anticancer therapy
Lin, C., Sukarieh, R., & Pelletier, J. (2023) · doi:10.1158/1535-7163.c.6531872.v1
Self-citationData from NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Dastur, A., Choi, A., Costa, C., Yin, X., Williams, A. F., McClanaghan, J., Greenberg, M., Roderick, J. E., Patel, N. U., Boisvert, J. L., et al. (2023) · doi:10.1158/1078-0432.c.6528492.v1
Lee, I., Doepner, M., Weissenrieder, J., Majer, A. D., Mercado, S., Estell, A., Natale, C. A., Sung, P. J., Foskett, J. K., Carroll, M. P., et al. (2023) · doi:10.1158/2767-9764.c.6749782.v1
Wang, X., Cornish, A. E., Do, M., Brunner, J. S., Hsu, T.-W., Xu, Z., Malik, I., Edwards, C., Capistrano, K. J., Zhang, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.03.587917
Well Met: RIPK1 senses S-adenosyl methionine to ensure cell survival
Sharma, P., & Green, D. R. (2025) · Life Metabolism · doi:10.1093/lifemeta/loaf033
Bornkamm, G. W., Kelly, G. L., & Ross, A. M. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_301 · Cited by 2
Ji, Q., Jiang, X., Li, X., Cao, C., Zhang, X., Zhou, M., Ma, S., & Chen, C. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06841-4
Caractérisation et études précliniques d'un nouvel inhibiteur naturel de MCL-1
Daressy, F. (2020) · theses.fr (ABES) · doi:10.70675/4e4153f4zba2dz49bcz9862z38251f3f7882
Li, H., Ju, R., Zhang, P., Jia, C., Xue, T., Wang, S., Zhu, X., Zhu, R., Luo, J., Jing, X., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02337-8
Molecular determinants of Bortezomib sensitivity and resistance in multiple myeloma
Hossain, J., Choudhury, D., Bhattacharyya, S., Vedeshachaitanya, B., & Malakar, P. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101303
Metadata
- Authors
- Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., Kogan, S. C., Nadon, R., Housman, D. E., Lowe, S. W., & Pelletier, J.
- Affiliations
- *Department of Biochemistry,
- Cold Spring Harbor Laboratory (US)
- Memorial Sloan Kettering Cancer Center (US)
- Molecular Oncology Research Institute, 750 Washington Street, Tufts–New England Medical Center, Box 5609, Boston, MA 02111;
- Tufts University (US)
- University of California, San Francisco (US)
- McGill University and Génome Québec Innovation Centre (CA)
- Massachusetts Institute of Technology (US)
- Howard Hughes Medical Institute (US)
- McGill University (CA)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-05
- Volume
- 105
- Issue
- 31
- Pages
- 10853-10858
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2504845
- OpenAlex
- W2024841712
- Cited by
- 285
- References
- 29
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 6 · 2023: 13 · 2022: 19 · 2021: 14 · 2020: 15 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 17 · 2015: 30 · 2014: 16 · 2013: 24 · 2012: 17
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- Brigham and Women's Hospital
- Canadian Breast Cancer Research Alliance
- National Institutes of Health (CA87497)
- Canadian Institutes of Health Research
- National Cancer Institute (CA-87497, P01CA087497, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- mTORC1, Mcl-1, translational regulation, TSC2, PI3K/Akt signaling, rapamycin, apoptosis, Eμ-Myc lymphoma, chemosensitivity, mTORC1 inhibitors, Bcl-2 family proteins, tumor cell survival
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Tuberous Sclerosis Complex 2 Protein, Animals, Lymphoma, Proteins, Transcription Factors, Immunoblotting, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-bcl-2, Sirolimus, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Proteins, Multiprotein Complexes, Immunoprecipitation, Mice, TOR Serine-Threonine Kinases, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.